Literature DB >> 21871532

5-HTTLPR genotype and gender, but not chronic fluoxetine administration, are associated with cortical TREK1 protein expression in rhesus macaques.

R Bogdan1, H Fitzgibbon, W L Woolverton, C L Bethea, A H Iyo, C A Stockmeier, P B Kyle, M C Austin.   

Abstract

TREK1 is a widely expressed background potassium channel. Similar to mice treated with selective serotonin reuptake inhibitors (SSRIs), TREK1 knockout mice are resistant to depression-like behavior and have elevated serotonin levels leading to speculation that TREK1 inhibition may contribute to the therapeutic effects of SSRIs. This study examined how chronic fluoxetine administration and a common functional polymorphism in the serotonin-transporter-linked promoter region (5-HTTLPR) influence cortical TREK1 expression in 24 rhesus monkeys. The short rh5-HTTLPR allele as well as female gender were associated with reduced cortical TREK1 protein expression but chronic SSRI administration had no effect. These results suggest that serotonin may influence TREK1, but that chronic SSRI treatment does not result in long lasting changes in cortical TREK1 protein expression. TREK1 gender differences may be related to gender differences in serotonin and require further research.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871532      PMCID: PMC3178708          DOI: 10.1016/j.neulet.2011.08.005

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  Early experience and serotonin transporter gene variation interact to influence primate CNS function.

Authors:  A J Bennett; K P Lesch; A Heils; J C Long; J G Lorenz; S E Shoaf; M Champoux; S J Suomi; M V Linnoila; J D Higley
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 2.  Serotonergic vulnerability and depression: assumptions, experimental evidence and implications.

Authors:  L A W Jans; W J Riedel; C R Markus; A Blokland
Journal:  Mol Psychiatry       Date:  2006-12-12       Impact factor: 15.992

3.  TREKing toward new antidepressants.

Authors:  Joshua A Gordon; Rene Hen
Journal:  Nat Neurosci       Date:  2006-09       Impact factor: 24.884

Review 4.  The neuronal background K2P channels: focus on TREK1.

Authors:  Eric Honoré
Journal:  Nat Rev Neurosci       Date:  2007-04       Impact factor: 34.870

Review 5.  Clinical pharmacology and pharmacokinetics of fluoxetine: a review.

Authors:  R F Bergstrom; L Lemberger; N A Farid; R L Wolen
Journal:  Br J Psychiatry Suppl       Date:  1988-09

6.  Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.

Authors:  K P Lesch; D Bengel; A Heils; S Z Sabol; B D Greenberg; S Petri; J Benjamin; C R Müller; D H Hamer; D L Murphy
Journal:  Science       Date:  1996-11-29       Impact factor: 47.728

7.  Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine.

Authors:  Louise E Kennard; Justin R Chumbley; Kishani M Ranatunga; Stephanie J Armstrong; Emma L Veale; Alistair Mathie
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

8.  Fluoxetine pharmacokinetics in pediatric patients.

Authors:  Timothy E Wilens; Louise Cohen; Joseph Biederman; Annah Abrams; Debarah Neft; Nagy Faird; Vikram Sinha
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

9.  Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype.

Authors:  Catherine Heurteaux; Guillaume Lucas; Nicolas Guy; Malika El Yacoubi; Susanne Thümmler; Xiao-Dong Peng; Florence Noble; Nicolas Blondeau; Catherine Widmann; Marc Borsotto; Gabriella Gobbi; Jean-Marie Vaugeois; Guy Debonnel; Michel Lazdunski
Journal:  Nat Neurosci       Date:  2006-08-13       Impact factor: 24.884

10.  Fluoxetine attenuates the inhibitory effect of glucocorticoid hormones on neurogenesis in vitro via a two-pore domain potassium channel, TREK-1.

Authors:  Guangjun Xi; Xiangrong Zhang; Ling Zhang; Yuxiu Sui; Jiaojie Hui; Shanshan Liu; Yingxin Wang; Lingjiang Li; Zhijun Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-11-11       Impact factor: 4.530

View more
  5 in total

Review 1.  Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept.

Authors:  M Borsotto; J Veyssiere; H Moha Ou Maati; C Devader; J Mazella; C Heurteaux
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

2.  Bone growth in juvenile rhesus monkeys is influenced by 5HTTLPR polymorphisms and interactions between 5HTTLPR polymorphisms and fluoxetine.

Authors:  Mari S Golub; Alicia M Bulleri; Casey E Hogrefe; Richard J Sherwood
Journal:  Bone       Date:  2015-06-09       Impact factor: 4.398

Review 3.  Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications.

Authors:  Guo-Lin Chen; Gregory M Miller
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-03       Impact factor: 3.568

4.  Key role of the 5-HT1A receptor addressing protein Yif1B in serotonin neurotransmission and SSRI treatment.

Authors:  Vincent Martin; Lionel Mathieu; Jorge Diaz; Haysam Salman; Jeanine Alterio; Caroline Chevarin; Laurence Lanfumey; Michel Hamon; Mark C Austin; Michèle Darmon; Craig A Stockmeier; Justine Masson
Journal:  J Psychiatry Neurosci       Date:  2020-09-01       Impact factor: 6.186

5.  Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant.

Authors:  Nicolas Vallée; Kate Lambrechts; Sébastien De Maistre; Perrine Royal; Jean Mazella; Marc Borsotto; Catherine Heurteaux; Jacques Abraini; Jean-Jacques Risso; Jean-Eric Blatteau
Journal:  Front Physiol       Date:  2016-02-16       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.